Sol Gel Technologies (NASDAQ:SLGL) Releases Earnings Results, Misses Expectations By $0.02 EPS

Sol Gel Technologies (NASDAQ:SLGL) announced its quarterly earnings data on Tuesday. The company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.02), Fidelity Earnings reports. Sol Gel Technologies had a negative net margin of 223.99% and a negative return on equity of 71.98%.

Shares of NASDAQ:SLGL opened at $7.23 on Wednesday. The company’s fifty day moving average price is $9.81 and its 200 day moving average price is $9.82. Sol Gel Technologies has a 12 month low of $5.00 and a 12 month high of $21.00. The firm has a market capitalization of $141.20 million, a P/E ratio of -3.10 and a beta of 1.51.

SLGL has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Sol Gel Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th. HC Wainwright raised their price objective on shares of Sol Gel Technologies from $23.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. ValuEngine upgraded shares of Sol Gel Technologies from a “sell” rating to a “hold” rating in a report on Friday, March 13th. Raymond James raised their price objective on shares of Sol Gel Technologies from $21.00 to $23.00 and gave the company a “strong-buy” rating in a report on Monday, December 30th. Finally, JMP Securities raised their price objective on shares of Sol Gel Technologies from $20.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, December 31st. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $23.00.

About Sol Gel Technologies

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

See Also: What does it mean to hold a stock in street name?

Earnings History for Sol Gel Technologies (NASDAQ:SLGL)

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.